AtaiBeckley (ATAI) Depreciation & Amortization (CF) (2020 - 2026)
AtaiBeckley (ATAI) posted Depreciation & Amortization (CF) of $233000.0 for Q3 2025, up 2.64% sequentially from $227000.0 in Q2 2025, and up 180.72% YoY from $83000.0 in Q3 2024.
Analysis
AtaiBeckley (ATAI) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
AtaiBeckley's Depreciation & Amortization (CF) history runs 2 years deep, the most recent figure standing at $167000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 22.69% year-over-year to $167000.0; the TTM figure through Mar 2026 stood at $383000.0 (changed N/A YoY), while the FY2025 annual figure was $1.0 million, up 113.95% from the prior year.
- Depreciation & Amortization (CF) climbed to $233000.0 in Q3 2025 per ATAI's latest filing, from $227000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $216000.0 in Q1 2025, with the low at $167000.0 in Q1 2026.
- A 5-year average of $88578.9 and a median of $74000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2021 and 2022: Depreciation & Amortization (CF) plunged 240.0% in 2021, then jumped 900.0% in 2022.
- Over 5 years, Depreciation & Amortization (CF) stood at $29000.0 in 2021, then surged by 82.76% to $53000.0 in 2022, then surged by 90.57% to $101000.0 in 2023, then jumped by 122.77% to $225000.0 in 2024, then grew by 3.56% to $233000.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $233000.0, $227000.0, and $216000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | AtaiBeckley | 1.61 Bn | 1.61 Bn | - | 233,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 215,000.00 |
| Mar 31, 2026 | 167,000.00 |
| Sep 30, 2025 | 233,000.00 |
| Jun 30, 2025 | 227,000.00 |
| Jun 30, 2025 | 227,000.00 |
| Mar 31, 2025 | 216,000.00 |
| Mar 31, 2025 | 216,000.00 |
| Dec 31, 2024 | 225,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 82,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Dec 31, 2023 | 101,000.00 |
| Sep 30, 2023 | 74,000.00 |
| Jun 30, 2023 | 79,000.00 |
| Mar 31, 2023 | 65,000.00 |
| Dec 31, 2022 | 53,000.00 |
| Sep 30, 2022 | 36,000.00 |
| Jun 30, 2022 | 19,000.00 |
| Mar 31, 2022 | 60,000.00 |
| Dec 31, 2021 | 29,000.00 |